[go: up one dir, main page]

EP2968326A1 - Inhibiteurs macrocycliques de la kinase inductible par un sel - Google Patents

Inhibiteurs macrocycliques de la kinase inductible par un sel

Info

Publication number
EP2968326A1
EP2968326A1 EP14719637.2A EP14719637A EP2968326A1 EP 2968326 A1 EP2968326 A1 EP 2968326A1 EP 14719637 A EP14719637 A EP 14719637A EP 2968326 A1 EP2968326 A1 EP 2968326A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
het
cycloalkyl
halo
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14719637.2A
Other languages
German (de)
English (en)
Inventor
Petra Marcella Françoise BLOM
Jan Marie Cyriel Jozef HOFLACK
Pascal André René BENDERITTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncodesign SA
Oncodesign Services SA
Original Assignee
Oncodesign SA
Oncodesign Services SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncodesign SA, Oncodesign Services SA filed Critical Oncodesign SA
Priority to EP14719637.2A priority Critical patent/EP2968326A1/fr
Priority claimed from PCT/EP2014/055168 external-priority patent/WO2014140313A1/fr
Publication of EP2968326A1 publication Critical patent/EP2968326A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Definitions

  • the present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of SIK kinase, more in particular SIK1 , SIK2 and/or SIK3 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of SIK-kinase associated diseases.
  • the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent. Background of the invention
  • Protein kinases constitute a large family of structurally related enzymes that are responsible for the control of a wide variety of signal transduction processes in the cell. They have been shown to be key regulators in most cellular functions including proliferation, cell metabolism, cell survival, apoptosis, DNA damage repair, cell motility... Uncontrolled signalling due to defective control of protein phosphorylation has been implicated in a number of diseases, including, for example, cancer, inflammation, allergies, immune diseases, CNS disorders, angiogenesis...
  • AMPK Adenosine Monophosphate- activated Protein Kinase
  • SIK Salt-lnducible Kinases
  • SIK1 also referred as SNF1 -Like Kinase (SNF1 LK) or Myocardial Snfl -like Kinase (MSK)
  • SIK2 SNF1 LK2 or KIAA0781
  • SIK3 KIAA0999
  • SIK1 has a role in the fine-tuning of steroidogenic enzyme production during the initial phase of steroidogenesis (Mol. Endocrinol. (2001 ) 15: 1264-1276).
  • SIK2 is induced by insulin, hormones, and differentiation factors in multiples cell types (adipocytes, neurons, macrophages, myocytes) and promotes cellular differentiation.
  • CREB cAMP Responsive Element Binding protein
  • IFS1 Insulin Receptor Substrate-1
  • MEF2 Myocyte Enhancer Factor 2
  • SIK2 modulates the gene transcription through the phosphorylation of substrates leading to their nuclear export, such as the transcriptional activator complexes TORC (Transducer Of Regulated CREB activity) or the transcriptional inhibitor HDAC4 (Histone Deacetylase 4).
  • SIK3 chondrocyte differentiation
  • SIK1 reduced hepatic triacylglycerol levels and lipogenic gene expression (The Journal of Biological Chemistry (2009) 284: 10446-10452).
  • members of the SIK family are emerging as hormones and nutrients sensors, which modulate key transcriptional processes such as steroid hormone biosynthesis by the adrenal cortex, insulin signalling in adipocytes, or inflammatory cytokines in macrophages.
  • SIK inhibition might also have application in cosmetology or pigmentation-related diseases to induce melanogenesis.
  • SIK2 plays a key role in the initiation of mitosis. It localizes at the centrosome where it phosphorylates the centrosome linker protein, C-Nap1 , and its depletion blocked centrosome separation in mitosis (Cancer Cell (2010) 18: 109-121 ). Depletion of SIK2 also delayed G1 /S transition and reduced the phosphorylation of AKT, a major protein associated with cell survival.
  • SIK proteins in the signalling pathways of nutrients and hormone sensors and of stress response, it was therefore an object of the present invention to provide a potent, selective, small molecule inhibitor of one or more of the SIK1 , SIK2 or SIK3 which can block specifically SIK-dependent stress response or sensitize tumour cells to chemo or - - targeted therapies.
  • a potent, selective, small molecule inhibitor of one or more of the SIK1 , SIK2 or SIK3 which can block specifically SIK-dependent stress response or sensitize tumour cells to chemo or - - targeted therapies.
  • it provides a therapeutic benefit in neurodegenerative disorders, pigmentation-related diseases and cancer as well as in cardiac, metabolic, autoimmune and inflammatory diseases characterized in increased stress responses and/or dysregulated SIK kinase activity; hereinafter referred to as 'disorders associated with SIK kinase activity'.
  • the macrocyclic compounds described herein act as SIK kinase inhibitors, in particular SIK1 , SIK2 and/or SIK3 kinase inhibitors, and are thus very useful in the prevention and/or treatment of SIK-kinase associated diseases.
  • the present invention provides a compound of Formula I or a stereoisomer, tautomer, racemic, metabolite, pro- or redrug, salt, hydrate, N-oxide form, or solvate thereof,
  • A-i and A 2 are selected from C and N; wherein when A-i is C, then A 2 is N; and wherein when A 2 is C, then A-, is N;
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -NR-nR 12 , -0-Ci_ 6 alkyl, and -S-Ci_ 6 alkyl;
  • R 2 is selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -
  • R 3 is selected from -H, -halo, -OH, -C 1-6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • each of said -d- 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • R 4 is independently selected from -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -NR 17 R 18 ,
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -C 3 . 6 cycloalkyl, -Ar- ⁇ , -Het 9 , and -NR 23 R 24 ;
  • R 9 R-io, R11 , Ri 2 , Ri 3 , Ri4.
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • R 51 and R 52 are each independently selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_
  • R 42 is selected from -H, -OH, -halo, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -NR 46 R 47 , -C 3 . 6 cycloalkyl, -Ar 9 and -Het 8 ; - -
  • R 43 is selected from -H -d- 6 alkyl, and -C 3 . 6 cycloalkyl; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -O-C1- 6alkyl, -S-Ci_ 6 alkyl, -Het 5 , -C 3 . 6 cycloalkyl -Ar 4 , and -NR44R45;
  • Y is selected from a direct bond, -CHR 42 -, -0-, -S-, and -NR 43 -;
  • Ar- ⁇ , Ar 2 , Ar 3 , Ar 4 , Ar 5 , Ar 6 , Ar 7 , Ar 8 , Ar 9 , Ar 10 and Ar-n are each independently a 5- to 10-membered aromatic heterocycle optionally comprising 1 or 2 heteroatoms selected from O, N and S; each of said Ar- ⁇ , Ar 2 , Ar 3 , Ar 4 , Ar 5 , Ar 6 , Ar 7 , Ar 8 , Ar 9 , and Ar 10 being optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S- Ci- 6 alkyl, and -NR 19 R 20 ; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 -halo;
  • Z-i, Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from C and N;
  • n and n are each independently 1 , 2, 3, or 4;
  • SIK-kinase associated disease for use in the diagnosis, prevention and/or treatment of a SIK-kinase associated disease.
  • the present invention provides a compound of Formula I or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof, wherein
  • R-i and R 41 are each independently selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_
  • each of said -d- 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -NR-n R 12 , -0-Ci_ 6 alkyl, and -S-Ci_ 6 alkyl;
  • R 2 is selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, - Het 3 , -Ar 2 , and -NRi 3 R M ;
  • R 3 is selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • R 4 is independently selected from -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -NR 17 R 18 ,
  • R 5 and R 7 are each independently selected from -H, -OH, -halo, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • R 9 R10, R11 , Ri 2 , R"i 3 , Ri 4 , R15. R16. Ri7 > R18. Ri9.
  • R20. R21. R22. R23. R24. R25. R26. R2 7 . R28. R29. R30.
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -C 3 . 6 cycloalkyl, -Het 7 , -Ar 5 and -NR 51 R 52 ;
  • R 5 i and R 52 are each independently selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_
  • R 42 is selected from -H, -OH, -halo, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -NR 46 R 4 7, -C 3 . 6 cycloalkyl, -Ar 9 and -Het 8 ;
  • R 43 is selected from -H -Ci_ 6 alkyl, and -C 3 . 6 cycloalkyl; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_
  • Y is selected from a direct bond, -CHR 42 -, -0-, -S-, and -NR 43 -;
  • Ar- ⁇ , Ar 2 , Ar 3 , Ar 4 , Ar 5 , Ar 6 , Ar 7 , Ar 8 , Ar 9 , Ar 10 and Ar-n are each independently a 5- to 10-membered aromatic heterocycle optionally comprising 1 or 2 heteroatoms selected from O, N and S; each of said Ar- ⁇ , Ar 2 , Ar 3 , Ar 4 , Ar 5 , Ar 6 , Ar 7 , Ar 8 , Ar 9 , and Ar 10 being optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S- Ci- 6 alkyl, and -NR 19 R 20 ; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 -halo;
  • Het- ⁇ , Het 2 , Het 3 , Het 4 , Het 5 , Het 6 , Het 7 , Het 8 , Het 9 , Het 10 , and Het 12 are each independently a 4- to 10-membered heterocycle having from 1 to 3 heteroatoms selected from O, N and S, wherein each of said Het- ⁇ , Het 2 , Het 3 , He , Het 5 , Het 6 , Het 7 , Het 8 , Het 9 , Het 10 , and Het 12 is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -d.
  • each of said -d- 6alkyl is optionally and independently substituted with from 1 to 3 -halo;
  • Z-i , Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from C and N;
  • n and n are each independently 1 , 2, 3, or 4;
  • SIK-kinase associated disease for use in the diagnosis, prevention and/or treatment of a SIK-kinase associated disease.
  • the present invention provides a compound of Formula I or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof, wherein
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -NR-nR 12 , -0-Ci_ 6 alkyl, and -S-Ci_ 6 alkyl;
  • R 2 is selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, - Het 3 , -Ar 2 , and -NRi 3 R M ;
  • R 3 is selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • R 4 is independently selected from -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -NR 17 R 18 ,
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -C 3 . 6 cycloalkyl, -Ar- ⁇ , -Het 9 , and -NR 23 R 24 ;
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • R 51 and R 52 are each independently selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_
  • R 42 is selected from -H, -OH, -halo, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -NR 46 R 47 , -C 3 . 6 cycloalkyl, -Ar 9 and -Het 8 ;
  • R 43 is selected from -H -Ci_ 6 alkyl, and -C 3 . 6 cycloalkyl; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -O-C1- 6alkyl, -S-Ci_ 6 alkyl, -Het 5 , -C 3 . 6 cycloalkyl -Ar 4 , and -NR 44 R 45 ;
  • Y is selected from a direct bond, -CHR 42 -, -0-, -S-, and -NR 43 -;
  • Ar- ⁇ , Ar 2 , Ar 3 , Ar 4 , Ar 5 , Ar 6 , Ar 7 , Ar 8 , Ar 9 , Ar 10 and Ar-n are each independently a 5- to 10-membered aromatic heterocycle optionally comprising 1 or 2 heteroatoms selected from O, N and S; each of said Ar- ⁇ , Ar 2 , Ar 3 , Ar 4 , Ar 5 , Ar 6 , Ar 7 , Ar 8 , Ar 9 , and Ar 10 being optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S- Ci_ 6 alkyl, and -NR 19 R 20 ; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 -halo;
  • Het- ⁇ , Het 2 , Het 3 , Het 4 , Het 5 , Het 6 , Het 7 , Het 8 , Het 9 , Het 10 , and Het 12 are each independently a 4- to 10-membered heterocycle having from 1 to 3 heteroatoms selected from O, N and S, wherein - - each of said Het- ⁇ , Het 2 , Het 3 , He , Het 5 , Het 6 , Het 7 , Het 8 , Het 9 , Het 10 , and Het 12 is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -d.
  • Z-i , Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from C and N;
  • n and n are each independently 1 , 2, 3, or 4;
  • SIK-kinase associated disease for use in the diagnosis, prevention and/or treatment of a SIK-kinase associated disease.
  • the present invention provides a compound of Formula I or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof, wherein
  • A-i and A 2 are selected from C and N; wherein when A-i is C, then A 2 is N; and wherein when A 2 is C, then A-, is N;
  • R 3 is -H;
  • R-i / , R18, R R R 27 , and R 28 are each independently selected from -H, and -Ci_ 6 alkyl; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -Het 7 , and -NR 51 R 52 ;
  • R 51 and R 52 are each -Ci_ 6 alkyl
  • R 43 is -H
  • A is selected from -(CH 2 ) n -Y-(CH 2 ) m -, and -NR 6 -;
  • X-i is selected from -0-Ci_ 6 alkyl-, -S-Ci_ 6 alkyl- and -Ci_ 6 alkyl-NR 3 -;
  • X 2 is selected from -0-Ci_ 6 alkyl-, -S-Ci_ 6 alkyl-, and -Ci_ 6 alkyl-NR 2 ;
  • Y is -NR 43 -;
  • Het 6 and Het 7 are each independently selected from a 5- to 10-membered heterocycle having from 1 to 3 heteroatoms selected from O, N and S;
  • Z-i , Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from C and N;
  • n and n are each independently 1 , 2, 3, or 4;
  • SIK-kinase associated disease for use in the diagnosis, prevention and/or treatment of a SIK-kinase associated disease.
  • the present invention provides a compound of Formula I or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof, wherein
  • R 3 is -H
  • R 4 is -NR 17 R 18 ;
  • R-I7, R-I8, R 2 5, R 2 6, R27, and R 28 are each independently selected from -H, and -Ci_ 6 alkyl; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -Het 7 , and -NR 51 R 52 ;
  • R 51 and R 52 are each -Ci_ 6 alkyl
  • R 43 is -H
  • A is selected from -(CH 2 ) n -Y-(CH 2 ) m -, and -NR 6 -;
  • X-i is selected from -0-Ci_ 6 alkyl-, -S-Ci_ 6 alkyl- and -Ci_ 6 alkyl-NR 3 -;
  • X 2 is selected from -0-Ci_ 6 alkyl-, -S-Ci_ 6 alkyl-, and -Ci_ 6 alkyl-NR 2 ;
  • Y is -NR 43 -;
  • Het 6 and Het 7 are each independently selected from a 5- to 10-membered heterocycle having from 1 to 3 heteroatoms selected from O, N and S;
  • Z-i , Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from C and N;
  • n and n are each independently 1 , 2, 3, or 4;
  • SIK-kinase associated disease for use in the diagnosis, prevention and/or treatment of a SIK-kinase associated disease.
  • the present invention provides a compound of Formula I or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof, wherein
  • R 3 is -H; - -
  • R R18, R25, R R27, and R 28 are each independently selected from -H, and -Ci_ 6 alkyl; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -Het 7 , and -NR 51 R 5 2;
  • R51 and R 52 are each -Ci_ 6 alkyl
  • R 43 is -H
  • A is selected from -(CH 2 )n-Y-(CH 2 )m-, and -NR 6 -;
  • X-i is selected from -0-Ci_ 6 alkyl-, -S-Ci_ 6 alkyl- and -Ci_ 6 alkyl-NR 3 -;
  • X 2 is selected from -0-Ci_ 6 alkyl-, -S-Ci_ 6 alkyl-, and -Ci_ 6 alkyl-NR 2 ;
  • Y is -NR 43 -;
  • Het 6 and Het 7 are each independently selected from a 5- to 10-membered heterocycle having from
  • Z-i , Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from C and N;
  • n and n are each independently 1 , 2, 3, or 4;
  • SIK-kinase associated disease for use in the diagnosis, prevention and/or treatment of a SIK-kinase associated disease.
  • the present invention provides a compound according to the present invention for use in the diagnosis, prevention and/or treatment of a SIK-kinase associated disease; wherein the pyrazolopyrimidine or the imidazopyridazine moiety is linked to the aryl or heteroaryl moiety at position Z 4 or Z 5 , in accordance with the numbering as provided in Formula I.
  • the present invention provides a compound according to the present invention for use in the diagnosis, prevention and/or treatment of a SIK-kinase associated disease; wherein R-i is linked to the aryl or heteroaryl moiety at position Z-i , Z 2 or Z 3 , in accordance with the numbering as provided in Formula I.
  • the present invention provides a compound selected from the list comprising: - -
  • the SIK-kinase associated disease is selected from the list comprising neurodegenerative disorders, pigmentation-related diseases and cancer, as well as cardiac, metabolic, autoimmune and inflammatory diseases. - -
  • the present invention further provides a pharmaceutical composition for use in the prevention and/or treatment of a SIK-kinase associated disease comprising a compound according to this invention. Furthermore, the present invention provides the use of a compound or composition according to this invention, suitable for inhibiting the activity of a kinase; in particular a SIK kinase; or for the diagnosis, prevention and/or treatment of a SIK-kinase associated disease.
  • the present invention provides a method for prevention and/or treatment of a SIK-kinase associated disease; said method comprising administering to a subject in need thereof a compound or a composition according to the present invention.
  • the present invention provides a compound of Formula I or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof,
  • R-i and R 41 are each independently selected from -H, -halo, -OH, -d- 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_
  • each of said -d- 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -NR-n R 12 , -0-Ci_ 6 alkyl, and -S-Ci_ 6 alkyl;
  • R 2 is selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, - Het 3 , -Ar 2 , and -NRi 3 R M ;
  • R 3 is selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • R 4 is independently selected from -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -NR 17 R 18 ,
  • R 5 and R 7 are each independently selected from -H, -OH, -halo, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • R 9 R10, R11 , Ri 2 , R"i 3 , Ri 4 , R15. R16. Ri7 > R18. Ri9.
  • R20. R21. R22. R23. R24. R25. R26. R2 7 . R28. R29. R30.
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -C 3 . 6 cycloalkyl, -Het 7 , -Ar 5 and -NR 51 R 52 ;
  • R 5 i and R 52 are each independently selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_
  • R 42 is selected from -H, -OH, -halo, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -NR 46 R 4 7, -C 3 . 6 cycloalkyl, -Ar 9 and -Het 8 ;
  • R 43 is selected from -H -Ci_ 6 alkyl, and -C 3 . 6 cycloalkyl; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_
  • Y is selected from a direct bond, -CHR 42 -, -0-, -S-, and -NR 43 -;
  • Ar- ⁇ , Ar 2 , Ar 3 , Ar 4 , Ar 5 , Ar 6 , Ar 7 , Ar 8 , Ar 9 , Ar 10 and Ar-n are each independently a 5- to 10-membered aromatic heterocycle optionally comprising 1 or 2 heteroatoms selected from O, N and S; each of said Ar- ⁇ , Ar 2 , Ar 3 , Ar 4 , Ar 5 , Ar 6 , Ar 7 , Ar 8 , Ar 9 , and Ar 10 being optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S- Ci- 6 alkyl, and -NR 19 R 20 ; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 -halo;
  • Het- ⁇ , Het 2 , Het 3 , Het 4 , Het 5 , Het 6 , Het 7 , Het 8 , Het 9 , Het 10 , and Het 12 are each independently a 4- to 10-membered heterocycle having from 1 to 3 heteroatoms selected from O, N and S, wherein each of said Het- ⁇ , Het 2 , Het 3 , He , Het 5 , Het 6 , Het 7 , Het 8 , Het 9 , Het 10 , and Het 12 is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -d.
  • each of said -d- 6alkyl is optionally and independently substituted with from 1 to 3 -halo;
  • Z-i , Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from C and N;
  • n and n are each independently 1 , 2, 3, or 4;
  • SIK-kinase associated disease for use in the diagnosis, prevention and/or treatment of a SIK-kinase associated disease.
  • radicals can be read both ways.
  • A is such as the right part of the possible values of A (i.e.
  • X-i is such as the right part of the possible values of X-i (i.e.
  • X 2 is such as the left part of the possible values of X 2 (i.e.
  • X 2 is such as the right part of the possible values of X 2 (i.e.
  • alkyl by itself or as part of another substituent refers to fully saturated hydrocarbon radicals.
  • alkyl groups of this invention comprise from 1 to 6 carbon atoms.
  • Alkyl groups may be linear or branched and may be substituted as indicated herein.
  • the subscript refers to the number of carbon atoms that the named group may contain.
  • Ci_ 6 alkyl means an alkyl of one to six carbon atoms.
  • alkyl groups are methyl, ethyl, n-propyl, i-propyl, butyl, and its isomers (e.g.
  • C C6 alkyl includes all linear, branched, or cyclic alkyl groups with between 1 and 6 carbon atoms, and thus includes methyl, ethyl, n-propyl, i-propyl, butyl and its isomers (e.g. n-butyl, i-butyl and t-butyl); pentyl and its isomers, hexyl and its isomers, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • optionally substituted alkyi refers to an alkyi group optionally substituted with one or more substituents (for example 1 to 3 substituents, for example 1 , 2 or 3 substituents or 1 to 2 substituents) at any available point of attachment.
  • substituents include -halo, -OH, primary and secondary amides, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, heteroaryl, aryl, and the like.
  • cycloalkyl by itself or as part of another substituent is a cyclic alkyi group, that is to say, a monovalent, saturated, or unsaturated hydrocarbyl group having a cyclic structure.
  • Cycloalkyl includes all saturated or partially saturated (containing 1 or 2 double bonds) hydrocarbon groups having a cyclic structure. Cycloalkyl groups may comprise 3 or more carbon atoms in the ring and generally, according to this invention comprise from 3 to 6 atoms. Examples of cycloalkyl groups include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
  • alkyi groups as defined are divalent, i.e., with two single bonds for attachment to two other groups, they are termed "alkylene" groups.
  • alkylene groups includes methylene, ethylene, methylmethylene, trimethylene, propylene, tetramethylene, ethylethylene, 1 ,2- dimethylethylene, pentamethylene and hexamethylene.
  • alkylene groups of this invention preferably comprise the same number of carbon atoms as their alkyi counterparts. Where an alkylene or cycloalkylene biradical is present, connectivity to the molecular structure of which it forms part may be through a common carbon atom or different carbon atom. To illustrate this applying the asterisk nomenclature of this invention, a C 3 alkylene group may be for example *-CH 2 CH 2 CH 2 -*, *-CH(-CH 2 CH 3 )-*, or *-CH 2 CH(-CH 3 )-*. Likewise a C 3 cycloalkylene group may be
  • heterocycle refers to non-aromatic, fully saturated or partially unsaturated cyclic groups (for example, 3 to 6 membered monocyclic ring systems, or 8-10 membered bicyclic rings) which have at least one heteroatom in at least one carbon atom-containing ring.
  • Each ring of the heterocyclic group containing a heteroatom may have 1 , 2, 3 or 4 heteroatoms selected from nitrogen atoms, oxygen atoms and/or sulfur atoms.
  • An optionally substituted heterocyclic refers to a heterocyclic having optionally one or more substituents (for example 1 to 4 substituents, or for example 1 , 2, 3 or 4), selected from those defined above for substituted alkyi.
  • heterocyclic groups include piperidinyl, azetidinyl, imidazolinyl, imidazolidinyl, isoxazolinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, piperidyl, succinimidyl, 3H- indolyl, isoindolinyl, chromenyl, isochromanyl, xanthenyl, 2H-pyrrolyl, 1 -pyrrolinyl, 2-pyrrolinyl, 3- pyrrolinyl, pyrrolidinyl, 4H-quinolizinyl, 4aH-carbazolyl, 2-oxopiperazinyl, piperazinyl, homopiperazinyl, 2-pyrazolinyl, 3-pyrazolinyl, pyranyl, dihydro-2H-pyranyl, 4H-pyranyl, 3,4-dihydr
  • 8-10 membered heterocyclic groups are also meant to include spiro-groups, which are bicyclic compounds with both rings connected through a single atom, such as for example spiro[4.5]decane, which is a spiro compound consisting of a cyclohexane ring and a cyclopentane ring.
  • aryl refers to a polyunsaturated, aromatic hydrocarbyl group having from 5-10 atoms.
  • Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems enumerated herein.
  • Non-limiting examples of aryl comprise phenyl, biphenylyl, biphenylenyl, 5- or 6-tetralinyl, 1 -, 2-, 3-, 4-, 5-, 6-, 7-, or 8-azulenyl, 1 - or 2-naphthyl, 1 -, 2-, or 3- indenyl, 1 -, 2-, or 9-anthryl, 1 - 2-, 3-, 4-, or 5-acenaphtylenyl, 3-, 4-, or 5-acenaphtenyl, 1 -, 2-, 3-, 4- , or 10-phenanthryl, 1 - or 2-pentalenyl, 1 , 2-, 3-, or 4-fluorenyl, 4- or 5-indany
  • the aryl ring can optionally be substituted by one or more substituents.
  • An "optionally substituted aryl” refers to an aryl having optionally one or more substituents (for example 1 to 5 substituents, for example 1 , 2, 3 or 4) at any available point of attachment, selected from those defined above for substituted alkyl.
  • heteroaryl ring where a carbon atom in an aryl group is replaced with a heteroatom, the resultant ring is referred to herein as a heteroaryl ring.
  • heteroaryl refers but is not limited to 5 to 10 carbon-atom aromatic rings in which one or more carbon atoms can be replaced by oxygen, nitrogen or sulfur atoms.
  • Non-limiting examples of such heteroaryl include: pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridinyl, pyrimidyl, pyrazinyl, pyridazinyl, oxazinyl, dioxinyl, thiazinyl, triazinyl, imidazo[2,1 -b][1 ,3]thiazolyl, thieno[3,
  • an “optionally substituted heteroaryl” refers to a heteroaryl having optionally one or more substituents (for example 1 to 4 substituents, for example 1 , 2, 3 or 4), selected from those defined above for substituted alkyl.
  • halo or halogen as a group or part of a group is generic for fluoro, chloro, bromo, or iodo, as well as any suitable isotope thereof.
  • substituted is meant to indicate that one or more hydrogens on the atom indicated in the expression using “substituted” is replaced with a selection from the indicated group, provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a chemically stable compound, i.e. a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into a therapeutic and/or diagnostic agent.
  • groups may be optionally substituted, such groups may be substituted once or more, and preferably once, twice or thrice.
  • Substituents may be selected from, those defined above for substituted alkyl.
  • alkyl, aryl, or cycloalkyl each being optionally substituted with” or “alkyl, aryl, or cycloalkyl, optionally substituted with” refers to optionally substituted alkyl, optionally substituted aryl and optionally substituted cycloalkyl.
  • the compounds of the invention may exist in the form of different isomers and/or tautomers, including but not limited to geometrical isomers, conformational isomers, E/Z-isomers, stereochemical isomers (i.e. enantiomers and diastereoisomers) and isomers that correspond to the presence of the same substituents on different positions of the rings present in the compounds of the invention. All such possible isomers, tautomers and mixtures thereof are included within the scope of the invention.
  • the invention includes isotopically-labelled compounds and salts, which are identical to compounds of formula (I), but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number most commonly found in nature.
  • isotopes that can be incorporated into compounds of formula (I) are isotopes of hydrogen, carbon, nitrogen, fluorine, such as 3 H, C, 3 N, 4 C, 5 0 and 8 F.
  • Such isotopically-labelled compounds of formula (I) are useful in drug and/or substrate tissue distribution assays.
  • C and 8 F isotopes are particularly useful in PET (Positron Emission Tomography).
  • PET is useful as a diagnostic or treatment follow-up tool that can be applied in a translational manner in a preclinical and clinical setting. It also has applications in PK determination of compounds, including biodistribution.
  • Isotopically labeled compounds of formula (I) can generally be prepared by carrying out the procedures disclosed below, by substituting a readily available non-isotopically labeled reagent with an isotopically labeled reagent.
  • the term "compounds of the invention” or a similar term is meant to include the compounds of general Formula I and any subgroup thereof. This term also refers to the compounds as depicted in Table 1 , their derivatives, /v-oxides, salts, solvates, - - hydrates, stereoisomeric forms, racemic mixtures, tautomeric forms, optical isomers, analogues, pro-drugs, esters, and metabolites, as well as their quaternized nitrogen analogues.
  • the /v-oxide forms of said compounds are meant to comprise compounds wherein one or several nitrogen atoms are oxidized to the so-called /v-oxide.
  • a compound means one compound or more than one compound.
  • the present invention provides compounds of Formula I or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof; for use in the diagnosis prevention and/or treatment of a SIK-kinase associated disease; wherein one or more of the following applies
  • A-i and A 2 are selected from C and N; wherein when A-i is C, then A 2 is N; and wherein when A 2 is C, then A-, is N;
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -NR-nR 12 , -0-Ci_ 6 alkyl, and -S-Ci_ 6 alkyl;
  • R 2 is selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -
  • R 3 is selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • R 4 is independently selected from -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -NR 17 R 18 , -C 3 . 6 cycloalkyl, -Ar 8 and -Het 4 ;
  • each of said -Ci_ 6 alkyl is optionally and independently substituted - - with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -C 3 . 6 cycloalkyl, -Ar- ⁇ , -Het 9 , and -NR23R24;
  • Rg R10, R11, Ri 2 , R"i 3 , Ri 4 , R15. R16. Ri7. R18. Ri9.
  • R20 R21. R22. R23. R24. R25. R26. R27. R28. R29. R30.
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -C 3 . 6 cycloalkyl, -Het 7 , -Ar 5 and -NR 51 R 52 ;
  • R51 and R 52 are each independently selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_
  • R 42 is selected from -H, -OH, -halo, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -NR 46 R 47 , -C 3 . 6 cycloalkyl, -Ar 9 and -Het 8 ;
  • R 43 is selected from -H -Ci_ 6 alkyl, and -C 3 . 6 cycloalkyl; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -O-C1-
  • Y is selected from a direct bond, -CHR 42 -, -0-, -S-, and -NR 43 -;
  • Ar- ⁇ , Ar 2 , Ar 3 , Ar 4 , Ar 5 , Ar 6 , Ar 7 , Ar 8 , Ar 9 , Ar 10 and Ar-n are each independently a 5- to 10-membered aromatic heterocycle optionally comprising 1 or 2 heteroatoms selected from O, N and S; each of said Ar- ⁇ , Ar 2 , Ar 3 , Ar 4 , Ar 5 , Ar 6 , Ar 7 , Ar 8 , Ar 9 , and Ar 10 being optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-
  • Ci- 6 alkyl, and -NR 19 R 20 wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 -halo;
  • Z-i , Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from C and N;
  • n are each independently 1 , 2, 3, or 4.
  • X-i , and X 2 as used herein, represent biradicals, which taken together with the radicals to which they are attached form a macrocyclic pyrazolopyrimidine compound.
  • Said biradicals may be present in either of both directions in the macrocyclic pyrazolopyrimidine, but are preferably present in the direction as described below:
  • the present invention provides compounds of formula I or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof, for use in the diagnosis, prevention and/or treatment of a SIK-kinase associated disease wherein
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -NR-nR 12 , -0-Ci_ 6 alkyl, and -S-Ci_ 6 alkyl;
  • R 2 is selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, - Het 3 , -Ar 2 , and -NR 13 R 14 ;
  • R 3 is selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • R 4 is independently selected from -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -NR 17 R 18 ,
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -C 3 . 6 cycloalkyl, -Ar- ⁇ , -Het 9 , and -NR 23 R 24 ;
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -C 3 . 6 cycloalkyl, -Het 7 , -Ar 5 and -NR 51 R 52 ;
  • R 51 and R 52 are each independently selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_
  • R 42 is selected from -H, -OH, -halo, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -NR 46 R 47 , -C 3 . 6 cycloalkyl, -Ar 9 and -Het 8 ;
  • R 43 is selected from -H -Ci_ 6 alkyl, and -C 3 . 6 cycloalkyl; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6alkyl, -S-Ci_ 6 alkyl, -Het 5 , -C 3 . 6 cycloalkyl -Ar 4 , and -NR 44 R 45 ;
  • Y is selected from a direct bond, -CHR 42 -, -0-, -S-, and -NR 43 -;
  • Ar- ⁇ , Ar 2 , Ar 3 , Ar 4 , Ar 5 , Ar 6 , Ar 7 , Ar 8 , Ar 9 , Ar 10 and Ar-n are each independently a 5- to 10-membered aromatic heterocycle optionally comprising 1 or 2 heteroatoms selected from O, N and S; each of said Ar- ⁇ , Ar 2 , Ar 3 , Ar 4 , Ar 5 , Ar 6 , Ar 7 , Ar 8 , Ar 9 , and Ar 10 being optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S- Ci- 6 alkyl, and -NR 19 R 20 ; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 -halo; - - -
  • 6 alkyl is optionally and independently substituted with from 1 to 3 -halo
  • Z-i , Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from C and N;
  • n and n are each independently 1 , 2, 3, or 4;
  • SIK-kinase associated disease for use in the diagnosis, prevention and/or treatment of a SIK-kinase associated disease.
  • the present invention provides a compound of Formula I or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof, for use in the diagnosis, prevention and/or treatment of a SIK-kinase associated disease wherein
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -NR-nR 12 , -0-Ci_ 6 alkyl, and -S-Ci_ 6 alkyl;
  • R 2 is selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, - Het 3 , -Ar 2 , and -NRi 3 R M ;
  • R 3 is selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • R 4 is independently selected from -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -NR 17 R 18 ,
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -C 3 . 6 cycloalkyl, -Ar- ⁇ , -Het 9 , and -NR 23 R 24 ; - -
  • Rg R10, R11, Ri 2 , R"i 3 , Ri 4 , R15. R16. Ri7. R18. Ri9.
  • R20 R21. R22. R23. R24. R25. R26. R27. R28. R29. R30.
  • each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl,
  • R 51 and R 52 are each independently selected from -H, -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_
  • R 42 is selected from -H, -OH, -halo, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -NR 46 R 47 , -C 3 . 6 cycloalkyl,
  • R 43 is selected from -H -Ci_ 6 alkyl, and -C 3 . 6 cycloalkyl; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -O-C1- 6alkyl, -S-Ci_ 6 alkyl, -Het 5 , -C 3 . 6 cycloalkyl -Ar 4 , and -NR 44 R 45 ;
  • 6 alkyl- is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -Ci. 6 alkyl, -0-Ci. 6 alkyl, -S-Ci. 6 alkyl, -phenyl, and -NR 37 R 38 ;
  • -Ci_ 6 alkyl- is optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -d- 6 alkyl, -0-Ci_ 6 alkyl, -S-Ci_ 6 alkyl, -phenyl and -NR 39 R4o;
  • Y is selected from a direct bond, -CHR 42 -, -0-, -S-, and -NR 43 -;
  • Ar- ⁇ , Ar 2 , Ar 3 , Ar 4 , Ar 5 , Ar 6 , Ar 7 , Ar 8 , Ar 9 , Ar 10 and Ar-n are each independently a 5- to 10-membered aromatic heterocycle optionally comprising 1 or 2 heteroatoms selected from O, N and S; each of said Ar- ⁇ , Ar 2 , Ar 3 , Ar 4 , Ar 5 , Ar 6 , Ar 7 , Ar 8 , Ar 9 , and Ar 10 being optionally and independently substituted with from 1 to 3 substituents selected from -halo, -OH, -Ci_ 6 alkyl, -0-Ci_ 6 alkyl, -S- Ci- 6 alkyl, and -NR 19 R 2 o; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 -halo;
  • Z-i, Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from C and N;
  • n are each independently 1 , 2, 3, or 4.
  • the present invention provides a compound of Formula I or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof, wherein
  • A-i and A 2 are selected from C and N; wherein when A-i is C, then A 2 is N; and wherein when A 2 is C, then A-, is N;
  • R 3 is -H
  • R 4 is -NR-
  • 7 , R-is, R 25 , R 26 , R 27 , and R 28 are each independently selected from -H, and -Ci_ 6 alkyl; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -Het 7 , and -NR 51 R 52 ;
  • R 51 and R 52 are each -Ci_ 6 alkyl
  • R 3 is -H; - -
  • A is selected from -(CH 2 )n-Y-(CH 2 )m-, and -N R 6 -;
  • X-i is selected from -0-Ci_ 6 alkyl-, -S-Ci_ 6 alkyl- and -Ci. 6 alkyl-N R 3 -;
  • X 2 is selected from -0-Ci_ 6 alkyl-, -S-Ci_ 6 alkyl-, and -Ci. 6 alkyl-N R 2 ;
  • Het 6 and Het 7 are each independently selected from a 5- to 10-membered heterocycle having from 1 to 3 heteroatoms selected from O, N and S;
  • Z-i , Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from C and N;
  • n and n are each independently 1 , 2, 3, or 4;
  • SIK-kinase associated disease for use in the diagnosis, prevention and/or treatment of a SIK-kinase associated disease.
  • the present invention provides a compound of Formula I or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof, wherein
  • R 3 is -H
  • R 4 is -N R 17 R 18 ;
  • R-I7, R18, R 2 5, R 2 6, R27, and R 28 are each independently selected from -H, and -Ci_ 6 alkyl; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -Het 7 , and -N R 51 R 52 ;
  • R 51 and R 52 are each -Ci_ 6 alkyl
  • R 43 is -H
  • A is selected from -(CH 2 ) n -Y-(CH 2 ) m -, and -N R 6 -;
  • X-i is selected from -0-Ci_ 6 alkyl-, -S-Ci_ 6 alkyl- and -Ci_ 6 alkyl-N R 3 -;
  • X 2 is selected from -0-Ci_ 6 alkyl-, -S-Ci_ 6 alkyl-, and -Ci_ 6 alkyl-N R 2 ;
  • Y is -N R 43 -;
  • Het 6 and Het 7 are each independently selected from a 5- to 10-membered heterocycle having from 1 to 3 heteroatoms selected from O, N and S;
  • Z-i , Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from C and N ;
  • n and n are each independently 1 , 2, 3, or 4;
  • SIK-kinase associated disease for use in the diagnosis, prevention and/or treatment of a SIK-kinase associated disease.
  • the present invention provides a compound of Formula I or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof, wherein
  • R 3 is -H
  • R 4 is -NR 17 R 18 ;
  • R-I7, R-I8, R 2 5, R 2 6, R 27 , and R 28 are each independently selected from -H, and -Ci_ 6 alkyl; wherein each of said -Ci_ 6 alkyl is optionally and independently substituted with from 1 to 3 substituents selected from -Het 7 , and -NR 51 R 52 ;
  • R 51 and R 52 are each -Ci_ 6 alkyl
  • R 43 is -H
  • A is selected from -(CH 2 ) n -Y-(CH 2 ) m -, and -NR 6 -;
  • X-i is selected from -0-Ci_ 6 alkyl-, -S-Ci_ 6 alkyl- and -Ci_ 6 alkyl-NR 3 -;
  • X 2 is selected from -0-Ci_ 6 alkyl-, -S-Ci_ 6 alkyl-, and -Ci_ 6 alkyl-NR 2 ;
  • Y is -NR 43 -;
  • Het 6 and Het 7 are each independently selected from a 5- to 10-membered heterocycle having from 1 to 3 heteroatoms selected from O, N and S;
  • Z-i , Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from C and N;
  • n and n are each independently 1 , 2, 3, or 4;
  • SIK-kinase associated disease for use in the diagnosis, prevention and/or treatment of a SIK-kinase associated disease.
  • the pyrazolopyrimidine or the imidazopyridazine moiety is linked to the aryl or heteroaryl moiety at position Z 4 or Z 5 , in accordance with the numbering as provided in Formula I.
  • the R-i of the compounds according to this invention is preferably linked to the aryl or heteroaryl moiety at position Z-i , Z 2 or Z 3 , in accordance with the numbering as provided in Formula I. - -
  • the compounds of the present invention can be prepared according to the reaction schemes provided in the examples hereinafter, but those skilled in the art will appreciate that these are only illustrative for the invention and that the compounds of this invention can be prepared by any of several standard synthetic processes commonly used by those skilled in the art of organic chemistry.
  • Compounds of formula (I) are inhibitors of SIK kinase activity, in particular SIK1 , SIK2 and/or SIK3 kinase inhibitors, and are thus believed to be of potential use in the prevention and/or treatment of neurodegenerative disorders, pigmentation-related diseases and cancer, as well as cardiac, metabolic, autoimmune and inflammatory diseases.
  • Said inhibition may be effected in vitro and/or in vivo, and when effected in vivo, is preferably effected in a selective manner, as defined above.
  • SIK kinase-mediated condition means any disease or other deleterious condition in which the SIK kinase, in particular SIK1 , SIK2 and/or SIK3 kinase and/or mutants thereof is/are known to play a role.
  • SIK kinase-mediated condition or “disease” also means those diseases or conditions that are alleviated by treatment with a SIK kinase inhibitor, in particular a SIK1 , SIK2 and/or SIK3 kinase inhibitor. Accordingly, another embodiment of the present invention relates to treating or lessening the severity of one or more diseases in which the SIK kinase is known to play a role.
  • the compounds of the invention may be used as a free acid or base, and/or in the form of a pharmaceutically acceptable acid-addition and/or base-addition salt (e.g. obtained with non-toxic organic or inorganic acid or base), in the form of a hydrate, solvate and/or complex, and/or in the form or a pro-drug or pre-drug, such as an ester.
  • a pharmaceutically acceptable acid-addition and/or base-addition salt e.g. obtained with non-toxic organic or inorganic acid or base
  • solvate includes any combination which may be formed by a compound of this invention with a suitable inorganic solvent (e.g. hydrates) or organic solvent, such as but not limited to alcohols, ketones, esters and the like.
  • suitable inorganic solvent e.g. hydrates
  • organic solvent such as but not limited to alcohols, ketones, esters and the like.
  • the pharmaceutically acceptable salts of the compounds according to the invention include the conventional non-toxic salts or the quaternary ammonium salts which are formed, e.g., from inorganic or organic acids or bases.
  • acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalene-sulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tos, to
  • Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl-bromides and others.
  • Other pharmaceutically acceptable salts include the sulfate salt ethanolate and sulfate salts.
  • the compounds of the inventions may be formulated as a pharmaceutical preparation or pharmaceutical composition comprising at least one compound of the invention and at least one pharmaceutically acceptable carrier, diluent or excipient and/or adjuvant, and optionally one or more further pharmaceutically active compounds.
  • such a formulation may be in a form suitable for oral administration, for parenteral administration (such as by intravenous, intramuscular or subcutaneous injection or intravenous infusion), for administration by inhalation, by a skin patch, by an implant, by a suppository, etc..
  • Such suitable administration forms - which may be solid, semi- solid or liquid, depending on the manner of administration - as well as methods and carriers, diluents and excipients for use in the preparation thereof, will be clear to the skilled person; reference is again made to for instance US-A-6, 372,778, US-A-6,369,086, US-A-6,369,087 and US-A-6, 372,733, as well as to the standard handbooks, such as the latest edition of Remington's Pharmaceutical Sciences.
  • Such preparations include tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, creams, lotions, soft and hard gelatin capsules, suppositories, eye drops, sterile injectable solutions and sterile packaged powders (which are usually reconstituted prior to use) for administration as a bolus and/or for continuous administration, which may be formulated with carriers, excipients, and diluents that are suitable per se for such formulations, such as lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, polyethylene glycol, cellulose, (sterile) water, methylcellulose, methyl- and propy
  • the formulations can optionally contain - - other pharmaceutically active substances (which may or may not lead to a synergistic effect with the compounds of the invention) and other substances that are commonly used in pharmaceutical formulations, such as lubricating agents, wetting agents, emulsifying and suspending agents, dispersing agents, desintegrants, bulking agents, fillers, preserving agents, sweetening agents, flavoring agents, flow regulators, release agents, etc..
  • the compositions may also be formulated so as to provide rapid, sustained or delayed release of the active compound(s) contained therein, for example using liposomes or hydrophilic polymeric matrices based on natural gels or synthetic polymers.
  • the present invention encompasses a pharmaceutical composition comprising an effective amount of a compound according to the invention with a pharmaceutically acceptable cyclodextrin.
  • co-solvents such as alcohols may improve the solubility and/or the stability of the compounds.
  • addition of salts of the compounds of the invention can be more suitable due to their increased water solubility.
  • the compounds may advantageously be used in the form of a spray, ointment or transdermal patch or another suitable form for topical, transdermal and/or intradermal administration.
  • compositions may be formulated in a pharmaceutical formulation comprising a therapeutically effective amount of particles consisting of a solid dispersion of the compounds of the invention and one or more pharmaceutically acceptable water-soluble polymers.
  • a solid dispersion defines a system in a solid state (as opposed to a liquid or gaseous state) comprising at least two components, wherein one component is dispersed more or less evenly throughout the other component or components.
  • a solid solution When said dispersion of the components is such that the system is chemically and physically uniform or homogenous throughout or consists of one phase as defined in thermodynamics, such a solid dispersion is referred to as "a solid solution”.
  • Solid solutions are preferred physical systems because the components therein are usually readily bioavailable to the organisms to which they are administered.
  • Suitable surface modifiers can preferably be selected from known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products and surfactants. Preferred surface modifiers include nonionic and anionic surfactants.
  • Yet another interesting way of formulating the compounds according to the invention involves a pharmaceutical composition whereby the compounds are incorporated in hydrophilic polymers and applying this mixture as a coat film over many small beads, thus yielding a composition with good - - bio-availability which can conveniently be manufactured and which is suitable for preparing pharmaceutical dosage forms for oral administration.
  • Materials suitable for use as cores in the beads are manifold, provided that said materials are pharmaceutically acceptable and have appropriate dimensions and firmness. Examples of such materials are polymers, inorganic substances, organic substances, and saccharides and derivatives thereof.
  • the preparations may be prepared in a manner known per se, which usually involves mixing at least one compound according to the invention with the one or more pharmaceutically acceptable carriers, and, if desired, in combination with other pharmaceutical active compounds, when necessary under aseptic conditions.
  • the pharmaceutical preparations of the invention are preferably in a unit dosage form, and may be suitably packaged, for example in a box, blister, vial, bottle, sachet, ampoule or in any other suitable single-dose or multi-dose holder or container (which may be properly labeled); optionally with one or more leaflets containing product information and/or instructions for use.
  • unit dosages will contain between 1 and 1000 mg, and usually between 5 and 500 mg, of the at least one compound of the invention, e.g. about 10, 25, 50, 100, 200, 300 or 400 mg per unit dosage.
  • the compounds can be administered by a variety of routes including the oral, rectal, ocular, transdermal, subcutaneous, intravenous, intramuscular or intranasal routes, depending mainly on the specific preparation used and the condition to be treated or prevented, and with oral and intravenous administration usually being preferred.
  • the at least one compound of the invention will generally be administered in an "effective amount", by which is meant any amount of a compound of Formula or any subgroup thereof that, upon suitable administration, is sufficient to achieve the desired therapeutic or prophylactic effect in the individual to which it is administered.
  • such an effective amount will usually be between 0.01 to 1000 mg per kilogram body weight day of the patient per day, more often between 0.1 and 500 mg, such as between 1 and 250 mg, for example about 5, 10, 20, 50, 100, 150, 200 or 250 mg, per kilogram body weight day of the patient per day, which may be administered as a single daily dose, divided over one or more daily doses, or essentially continuously, e.g. using a drip infusion.
  • the amount(s) to be administered, the route of administration and the further treatment regimen may be determined by the treating clinician, depending on factors such as the age, gender and general condition of the patient and the nature and severity of the disease/symptoms to be treated.
  • said pharmaceutical composition can be administered separately at different times during the course of therapy or concurrently in divided or - - single combination forms.
  • the present invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly.
  • compositions of the present invention can be mixed with suitable additives, such as excipients, stabilizers, or inert diluents, and brought by means of the customary methods into the suitable administration forms, such as tablets, coated tablets, hard capsules, aqueous, alcoholic, or oily solutions.
  • suitable inert carriers are gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose, or starch, in particular, corn starch.
  • the preparation can be carried out both as dry and as moist granules.
  • Suitable oily excipients or solvents are vegetable or animal oils, such as sunflower oil or cod liver oil.
  • Suitable solvents for aqueous or alcoholic solutions are water, ethanol, sugar solutions, or mixtures thereof.
  • Polyethylene glycols and polypropylene glycols are also useful as further auxiliaries for other administration forms.
  • these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.
  • compositions When administered by nasal aerosol or inhalation, these compositions may be prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
  • Suitable pharmaceutical formulations for administration in the form of aerosols or sprays are, for example, solutions, suspensions or emulsions of the compounds of the invention or their physiologically tolerable salts in a pharmaceutically acceptable solvent, such as ethanol or water, or a mixture of such solvents.
  • the formulation can also additionally contain other pharmaceutical auxiliaries such as surfactants, emulsifiers and stabilizers as well as a propellant.
  • auxiliaries such as surfactants, emulsifiers and stabilizers as well as a propellant.
  • the compound according to the invention if desired with the substances customary therefore such as solubilizers, emulsifiers or further auxiliaries are brought into solution, suspension, or emulsion.
  • the compounds of the invention can also be lyophilized and the lyophilizates obtained used, for example, for the production of injection or infusion preparations.
  • Suitable solvents are, for example, water, physiological saline solution or alcohols, e.g.
  • injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally-acceptable diluents or solvents, such as mannitol, 1 ,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • suitable non-toxic, parenterally-acceptable diluents or solvents such as mannitol, 1 ,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • these formulations When rectally administered in the form of suppositories, these formulations may be prepared by mixing the compounds according to the invention with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.
  • a suitable non-irritating excipient such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.
  • the compounds and compositions of the invention are used orally or parenterally.
  • the compounds of this invention can be prepared by any of several standard synthetic processes commonly used by those skilled in the art of organic chemistry.
  • the compounds are generally prepared from starting materials which are either commercially available or prepared by standard means obvious to those skilled in the art.
  • the present invention provides compounds according to formula I, for use in the dia nosis, prevention and/or treatment of SIK-kinase associated diseases:
  • the compounds of formula (I) can be prepared as shown in scheme 1 below wherein a pyrazolo[1 ,5-a]pyrimidine or a imidazo[2,1 -f
  • the compound of formula (VI) can then be - - optionally deprotected if desired before cyclisation to form a compound of formula (VII).
  • the compound of formula (VII) can be optionally converted into a compound of general formula (I).
  • LGi and LG 2 each independently represent suitable leaving or functional groups
  • E represents a suitable functional group that can be used to form a direct bond between the (hetero-)aryl group and the scaffold.
  • D represents a functional group such as A or a protected functional group, which upon further reaction and/or deprotection produces a functional group such as A as defined in formula I;
  • the leaving groups LGi and LG 2 are advantageously a halo group such as a chlorine or a bromine group.
  • the reaction can be affected by a substitution for example by treating the compound of formula (II) with the compound of formula (III) in an organic solvent such as acetonitrile with an appropriate base such as for example diisopropylethylamine at an elevated temperature for example under reflux.
  • an appropriate base such as for example diisopropylethylamine
  • the compound of formula (IV) can optionally be protected with a suitable protecting group such as a tert-butyloxycarbonylamino group in a conventional manner for example by treatment with tert- butoxycarbonyl anhydride in basic conditions using for example triethylamine and 4- (dimethylamino)pyridine in a solvent such as tetrahydrofurane at an elevated temperature such as under reflux.
  • a suitable protecting group such as a tert-butyloxycarbonylamino group in a conventional manner for example by treatment with tert- butoxycarbonyl anhydride in basic conditions using for example triethylamine and 4- (dimethylamino)pyridine in a solvent such as tetrahydrofurane at an elevated temperature such as under reflux.
  • reaction of the resulting compound (IV) with a (hetero-)aryl compound of formula (V) is advantageously effected through the coupling of a boronic acid E or boronic ester E derivative of the (hetero-)aryl compound under Suzuki conditions using for example tetrakis(triphenylphosphine)palladium(0), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (Xphos) and potassium phosphate tribasic in a solvent mixture such as 1 ,4-dioxane/water at an elevated temperature for example under reflux.
  • a solvent mixture such as 1 ,4-dioxane/water at an elevated temperature for example under reflux.
  • the resulting compound of formula (VI) can optionally be treated to remove any desired protecting groups for example silyl ether groups such as tert-butyldimethylsilyl groups can be converted to the parent free hydroxy group. Such deprotection can be effected in a conventional manner for example using tetrabutylammonium fluoride in tetrahydrofuran at room temperature.
  • the resulting compound of formula (VI) can also optionally be treated to remove any desired protecting groups for example benzyl groups can be removed in a conventional manner for example using hydrogen gas and palladium on activated charcoal (10%) in a solvent such as methanol at a temperature such as room temperature.
  • the compound of formula (VI) can optionally be treated to remove any desired protecting groups for example tert-butyloxycarbonylamino groups can be converted to the parent free amino group.
  • deprotection can be effected in a conventional manner for example by treatment under acidic conditions for example using a 4N acetyl chloride solution in a solvent such as methanol at for example room temperature.
  • the cyclisation of the compound of formula (VI) can be effected for example under Mitsunobu conditions using for example diisopropyl azodicarboxylate and triphenylphosphine in a solvent mixture such as 2-methyl-1 ,4-dioxane and toluene at an elevated temperature such as 90°C.
  • the resulting compound of formula (VII) can optionally be treated to remove any desired protecting groups for example tert-butyloxycarbonylamino groups can be converted to the parent free amino group.
  • deprotection can be effected in a conventional manner for example by treatment under acidic conditions for example using a 4N hydrochloric acid solution in methanol at room temperature.
  • the deprotected compound can optionally be treated to form an amide compound of formula (I).
  • the reaction can advantageously be affected by treatment with an acylchloride and a base such as triethylamine in a solvent such as tetrahydrofuran at room temperature.
  • the reaction can also be affected using for example 0-(benzotriazol-1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) and diisopropylethylamine in a solvent such as N ,N- dimethylformamide at for example room temperature.
  • HBTU 0-(benzotriazol-1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
  • the compounds of formula (I) can also be prepared as shown in general scheme 2 below wherein a pyrazolo[1 ,5-a]pyrimidine or a imidazo[2,1 -f
  • the compound of formula (IX) can be optionally be converted into a compound of formula (IV) which is then reacted with a (hetero-)aryl of formula (V) to form a compound of formula (VI).
  • the compound of formula (VI) can then be optionally deprotected if desired before cyclisation to form a compound of formula (VII).
  • the compound of formula (VII) can be optionally converted into a compound of general formula (I).
  • LGi and LG 2 each independently represent suitable leaving or functional groups
  • E represents a suitable functional group that can be used to form a direct bond between the (hetero-)aryl group and the scaffold.
  • G represents a suitable functional group or protected functional group, which upon further reaction and/or deprotection produces a functional group such as D;
  • D represents a functional group such as A or a protected functional group, which upon further reaction and/or deprotection produces a functional group such as A as defined in formula I;
  • the leaving groups LGi and LG 2 are advantageously a halo group such as a chlorine or a bromine group.
  • the reaction can be affected by a substitution for example by treating the compound of formula (II) with the compound of formula (VIII) in an organic solvent such as tetrahydrofuran with an appropriate base such as for example sodium hydride at for example room temperature.
  • the compounds of formula (IX) can be deprotected using for example acidic conditions such as a 4N hydrochloric acid solution in methanol at room temperature.
  • the compounds of formula (IX) can be converted into compounds of formula (IV) by using for example a reductive amination.
  • the reaction can be affected by treating the compound of formula (IX) with an alhyde in the presence of a reducing agent such as sodium triacetoxy borohydride and a base such as triethylamine in a solvent such as dichloromethane at for example room temperature.
  • a reducing agent such as sodium triacetoxy borohydride
  • a base such as triethylamine
  • reaction of the compound with formula (IV) with a (hetero-)aryl compound of formula (V) is advantageously effected under Suzuki conditions using for example tetrakis(triphenylphosphine)palladium(0) and potassium phosphate tribasic in a solvent mixture such as 1 ,4-dioxane/water at an elevated temperature for example 80°C.
  • the resulting compound of formula (VI) can optionally be treated to remove any desired protecting groups for example silyl ether groups such as tert-butyldimethylsilyl groups can be converted to the parent free hydroxy group.
  • any desired protecting groups for example silyl ether groups such as tert-butyldimethylsilyl groups can be converted to the parent free hydroxy group.
  • deprotection can be effected using for example acetic acid in tetrahydrofuran at for example room temperature.
  • the compound of formula (VI) can optionally be treated to remove any desired protecting groups for example tert-butyloxycarbonylamino groups can be converted to the parent free amino group.
  • Such deprotection can be effected in a conventional manner for example by treatment under acidic conditions for example using a 4N acetyl chloride solution in a solvent such as methanol at for example room temperature.
  • the free hydroxyl group can be converted into a leaving group such as a chloride by reacting the hydroxyl group for example with thionyl chloride in the presence of a base such as pyridine in a solvent such as dichloromethane at an elevated temperature for example under reflux.
  • a leaving group such as a chloride
  • the cyclisation of the compound of formula (VII) can be advantageously effected under Williamson conditions using a base such as cesium carbonate in a solvent such as ⁇ , ⁇ -dimethylformamide at an elevated temperature such as 90°C.
  • a base such as cesium carbonate
  • a solvent such as ⁇ , ⁇ -dimethylformamide
  • Other condtions that can be used for the cyclisation of the compound of formula (VII) can be for example by treatment with 0-(benzotriazol-1 -yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate (HBTU) and ⁇ , ⁇ -diisopropylethylamine in a solvent such as ⁇ , ⁇ -dimethylformamide at for example room temperature.
  • HBTU 0-(benzotriazol-1 -yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate
  • the resulting compound of formula (VII) can optionally be treated to form a compound of formula (I).
  • the leaving groups LGi and LG 2 are advantageously a halo group such as a chlorine or a bromine group.
  • the reaction can be affected by a substitution for example by treating the compound of formula (II) with the compound of formula (VIII) in an organic solvent such as acetonitrile with an appropriate base such as for example diisopropylethylamine at an elevated temperature for example under reflux.
  • the resulting compound of formula (IX) can optionally be protected with a suitable protecting group such as a tert-butyloxycarbonylamino group in a conventional manner for example by treatment with tert-butoxycarbonyl anhydride in basic conditions using for example triethylamine and 4- (dimethylamino)pyridine in a solvent such as tetrahydrofuran at an elevated temperature such as under reflux.
  • a suitable protecting group such as a tert-butyloxycarbonylamino group in a conventional manner for example by treatment with tert-butoxycarbonyl anhydride in basic conditions using for example triethylamine and 4- (dimethylamino)pyridine in a solvent such as tetrahydrofuran at an elevated temperature such as under reflux.
  • reaction of the resulting compound (IX) with a (hetero-)aryl compound of formula (V) is advantageously effected through the coupling of a boronic acid E or boronic ester E derivative of the (hetero-)aryl compound under Suzuki conditions using for example tetrakis(triphenylphosphine)palladium(0), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (Xphos) and potassium phosphate tribasic in a solvent mixture such as 1 ,4-dioxane/water at an elevated temperature for example 80°C.
  • a solvent mixture such as 1 ,4-dioxane/water at an elevated temperature for example 80°C.
  • reaction of the resulting compound of formula (X) with a compound of formula (XI) which can be advantageously effected under Williamson conditions using a base such as potassium carbonate in a solvent such as acetonitrile at an elevated temperature such as under reflux.
  • This reaction can also be effected under Mitsunobu conditions using for example diisopropyl azodicarboxylate and triphenylphosphine in a solvent such as tetrahydrofuran at an elevated temperature such as 90°C. - -
  • the resulting compound of formula (XI) can optionally be treated to remove any desired protecting groups for example tert-butyloxycarbonylamino groups can be converted to the parent free amino group and for example ester groups can be converted to the parent free carboxylic acid groups.
  • deprotection can be effected in a conventional manner for example by treatment under acidic conditions for example using an aqueous 6N hydrochloric acid solution in a solvent such as acetoniitrile at an elevated temperature for example 60°C or using an acid such as trifluoroacetic acid in a solvent such as dichloromethane at for example room temperature.
  • the cyclisation of the compound of formula (XI) can be effected for example by treatment with O- (benzotriazol-1 -yl)-N,N ,N',N'-tetramethyluronium hexafluorophosphate (HBTU) and N,N- diisopropylethylamine in a solvent such as ⁇ , ⁇ -dimethylformamide at for example room temperature.
  • Example H78 is prepared following general scheme 1 .
  • the mixture was stirred at 90°C for 30 minutes.
  • the reaction mixture was cooled and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using dichloromethane and methanol as eluents (gradient elution from 0% to 10% methanol). The product fractions were collected and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using heptane - - and ethyl acetate as eluents (gradient elution from 0% to 100% ethyl acetate). The product fractions were collected and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using dichloromethane and methanol as eluents (gradient elution from 0% to 5% methanol). The product fractions were collected and the solvent was and the solvent was removed under reduced pressure.
  • Example H79 is prepared following general scheme 1 .
  • Example H78 (184 mg, 0.49 mmol) and triethylamine (204 ⁇ , 1 .47 mmol) were stirred in dry tetrahydrofuran (1 .5 ml). Cyclopropanecarbonyl chloride (40 ⁇ , 0.49 mmol) was added and the mixture was stirred at room temperature for 2 hours. The solvent was removed under reduced pressure. Methanol was added and the solid was filtered. The product was purified by reversed phase HPLC (HPLC method A). The product fractions were collected and the solvent was evaporated.
  • Example H80 is prepared following general scheme 1 .
  • Example H80 can be prepared following general scheme 1 .
  • Example B64 (78 mg, 0.198 mmol) was added to borane tetrahydrofuran complex (1 M solution in tetrahydrofuran, 4 ml) at 0 °C. The suspension was stirred at room temperature for 17 hours. The solvent was removed under reduced pressure. A 2 N HCI solution (4.4 ml) was added and the reaction mixture was refluxed for 1 hour. The pH of the solution was adjusted with 1 N sodium hydroxide to pH 7 and the solvent was removed under reduced pressure. The product was purified - - by reversed phase HPLC (HPLC method A). The product fractions were collected and the solvent was evaporated.
  • HPLC method A reversed phase HPLC
  • Example H82 can be prepared following general scheme 1 and according to the procedures described in the patent application WO2013/045653 A1 to obtain example 17.
  • Example H83 can be prepared following general scheme 1 and according to the procedures described in the patent application WO2013/045653 A1 to obtain example 5. - -
  • Example H84 can be prepared following general scheme 1 and according to the procedures described in the patent application WO2013/045653 A1 to obtain example 5.
  • the residue was purified by flash column chromatography over silica gel using dichloromethane and methanol as eluents (gradient elution from 0 % to 10 % of methanol). The product fractions were collected and the solvent was evaporated.
  • the residue was dissolved in ethyl acetate and washed with water and an aqueous saturated sodium bicarbonate solution. The organic layer was dried, filtered and the solvent was removed under reduced pressure. The residue was purified by flash column chromatography over silica gel using dichloromethane and methanol as eluents (gradient elution from 0 % to 5 % of methanol). The product fractions were collected and the solvent was evaporated.
  • the reaction mixture was cooled, diluted with ethyl acetate and the organic layer was washed with water and brine. The organic layer was dried, filtered and the solvent was removed under reduced pressure. The residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution from 20 % to 100 % of ethyl acetate). The product fractions were collected and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution from 30 % to 100 % of ethyl acetate). The product fractions were collected and the solvent was removed under reduced pressure.
  • reaction mixture was cooled and the solvent was removed under reduced pressure.
  • residue was purified by flash column chromatography over silica gel using using dichloromethane and methanol as eluents (gradient elution from 0 % to 5 % of methanol). The product fractions were collected and the solvent was removed under reduced pressure.
  • Example H86 is prepared following general scheme 1 . Preparation of intermediate 13
  • the reaction mixture was cooled and the solvent was removed under reduced pressure. Water was added and the product was extracted with ethyl acetate. The combined organic layers were dried, filtered and the solvent was removed under reduced pressure. The residue was purified by flash column chromatography over silica gel using using dichloromethane and methanol as eluents (gradient elution from 0 % to 10 % of methanol). The product fractions were collected and the solvent was removed under reduced pressure.
  • Example H87 is prepared following general scheme 2. Preparation of intermediate 18
  • the residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution from 0% to 30% ethyl acetate). The product fractions were collected and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution from 20 % to 100 % of ethyl acetate). The product fractions were collected and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution from 0 % to 50 % of ethyl acetate). The product fractions were collected and the solvent was removed under reduced pressure.
  • Tris(dibenzylideneacetone)dipalladium(0) (81 mg, 0.07 mmol) was added and the mixture was stirred under nitrogen gas at 80°C for 7 hours.
  • the reaction mixture was cooled and ethyl acetate was added.
  • the organic layer was washed with water and brine, dried, filtered and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution from 0 % to 50 % of ethyl acetate). The product fractions were collected and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using dichloromethane and methanol as eluents (gradient elution from 0 % to 4 % of ethyl methanol). The product fractions were collected and the solvent was removed under reduced pressure.
  • Example H88 is prepared following general scheme 1 and according to the procedures described in the patent application WO2013/045653 A1 to obtain example 18.
  • Example H89 is prepared following general scheme 3. Preparation of intermediate 25
  • the organic layer was dried, filtered and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution - - from 10 % to 80 % of ethyl acetate).
  • the product fractions were collected and the solvent was removed under reduced pressure.
  • the product was triturated with diethyl ether, filtered and dried under reduced pressure.
  • the reaction mixture was cooled, diluted with ethyl acetate and the organic layer was washed with water and brine. The organic layer was dried, filtered and the solvent was removed under reduced pressure. The residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution from 30 % to 100 % of ethyl acetate). The product fractions were collected and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution from 0 % to 40 % of ethyl acetate). The product fractions were collected and the solvent was removed under reduced pressure.
  • Example H90 can be prepared following general scheme 1 and according to the procedures described in the patent application WO2013/045653 A1 to obtain example 18.
  • Example H91 can be prepared following general scheme 1 .
  • Example H90 (62 mg, 0.16 mmol) and formaldehyde (14.6 ⁇ , 0.18 mmol) were dissolved in methanol (0.48 ml) and stirred for 30 minutes at room temperature.
  • Sodium triacetoxyborohydride (102 mg, 0.48 mmol) was added and the mixture was stirred at room temperature for 16 hours.
  • An aqueous saturated sodium bicarbonate solution was added and the aqueous layer was extracted with ethyl acetate. The organic layer was dried, filtered and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using dichloromethane and methanol as eluents (gradient elution from 0 % to 5 % of methanol). The product fractions were collected and the solvent was removed under reduced pressure.
  • Example H92 can be prepared following general scheme 1 and according to the procedures described in the patent application WO2013/045653 A1 to obtain example 18.
  • Example H93 can be prepared following general scheme 1 and according to the procedures described to obtain example H91 .
  • Example H94 can be prepared following general scheme 1 and according to the procedures described to obtain example H91 . - -
  • Example H96 can be prepared following general scheme 1 and according to the proceed described to obtain example H80.
  • Example H97 can be prepared following general scheme 1 . Preparation of intermediate 33
  • the residue was purified by flash column chromatography over silica gel using a mixture of dichloromethane/methanol (9:1 ) and methanol as eluents (gradient elution from 0 % to 40 % of methanol). The product fractions were collected and the solvent was removed under reduced pressure.
  • Example H98 can be prepared following general scheme 2.
  • the residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution from 0 % to 100 % of ethyl acetate). The product fractions were collected and the solvent was removed under reduced pressure.
  • Diisopropyl azodicarboxylate (12.18 ml, 60.23 mmol) was added drop wise at 0°C to a mixture of intermediate 34 (5.504 g, 20.08 mmol), isoindoline-1 ,3-dione (4.43 g, 30.12 mmol) and triphenylphosphine (15.8 g, 60.23 mmol) in dry 2-methyltetrahydrofuran (120 ml).
  • the solvent was removed under reduced pressure, the residue was dissolved in ethyl acetate and washed with - - brine.
  • the organic layer was dried, filtered and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution from 0 % to 50 % of ethyl acetate). The product fractions were collected and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution from 0 % to 100 % of ethyl acetate). The product fractions were collected and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using dichloromethane and methanol as eluents (gradient elution from 0 % to 50 % of methanol). The product fractions were collected and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution from 0 % to 100 % of ethyl acetate). The product fractions were collected and the solvent was removed under reduced pressure.
  • the mixture was stirred at 100°C overnight.
  • the reaction mixture was cooled, the solvent was removed under reduced pressure and ethyl acetate was added.
  • the organic layer was washed with water, dried, filtered and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution from 33 % to 100 % of ethyl acetate) and then by using then dichloromethane and methanol as eluents (gradient elution from 2 % to 10 % of methanol).
  • the product fractions were collected and the solvent was removed under reduced pressure.
  • Example H99 can be prepared following general scheme 2 and according to the procedures described to obtain example H98.
  • Example H100 can be prepared following general scheme 1 . Preparation of intermediate 43
  • tert-Butyl N-(3-bromopyrazolo[1 ,5-a]pyrimidin-5-yl)-N-[3-[tert-butoxycarbonyl-[2-(tert- butyl(dimethyl)silyl)oxyethyl]amino]propyl]carbamate can be prepared according to similar procedures described in the patent application WO2013/045653 A1 to obtain intermediate 23.
  • Tetrakis(triphenylphosphine)palladium(0) (185 mg, 0.16 mmol) and 2-dicyclohexylphosphino- 2',4',6'-triisopropylbiphenyl (Xphos) (234 mg, 0.49 mmol) were added and the mixture was stirred under nitrogen gas at 80°C for 16 hours.
  • the reaction mixture was cooled and a saturated aqueous sodium bicarbonate solution was added.
  • the aqueous layer was extracted with ethyl acetate.
  • the combined organic layers were dried, filtered and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution from 0% to 50% ethyl acetate). The product fractions were collected and the solvent was evaporated.
  • the residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution from 0 % to 70 % of ethyl acetate). The product fractions were collected and the solvent was removed under reduced pressure.
  • reaction mixture was cooled and the solvent was removed under reduced pressure.
  • residue was purified by flash column chromatography over silica gel using heptane and ethyl acetate as eluents (gradient elution from 0 % to 100 % of ethyl acetate). The product fractions were collected and the solvent was removed under reduced pressure.
  • the residue was purified by flash column chromatography over silica gel using dichloromethane and a mixture of dichloromethane and methanol (9:1 ) as eluents (gradient elution from 0 % to 10 % of the mixture of dichloromethane and methanol).
  • the product fractions were collected and the solvent was removed under reduced pressure.
  • A1 1 300 H89 273,3
  • SIK2 kinase The inhibition of SIK2 kinase was assessed using SIK2 recombinant protein in an in vitro peptide- based kinase assay.
  • a radiometric protein kinase assay ( 33 PanQinase ® Activity Assay) is used for measuring the kinase activity. All assays are performed in 96-well FlashPlatesTM from Perkin Elmer in a 50 ⁇ reaction volume. The reaction cocktail is 94ipette in 4 steps in the following order: 10 ⁇ I of non-radioactive ATP solution (in H20)
  • the assay for SIK2 contains 70 mM HEPES-NaOH pH 7.5, 3 mM MgCI 2 , 3 mM MnCI 2 , 3 ⁇ Na- orthovanadate, 1 .2 mM DTT, 50 ⁇ g/ml PEG20000, ATP (1 .0 ⁇ ), [ ⁇ - 33 ⁇ ]- ⁇ (approx. 5 x 10 05 cpm per well), protein kinase SIK2 (0,3 nM) and substrate (RBER-Chktide), 2,0 ⁇ g/50 ⁇ ).
  • the kinase is obtained from Invitrogen Corporation.
  • the reaction cocktails were incubated at 30° C for 60 minutes.
  • the reaction was stopped with 50 ⁇ of 2 % (v/v) H3PO4, plates were aspirated and washed two times with 200 ⁇ 0.9 % (w/v) NaCI.
  • Incorporation of 33 Pi was determined with a microplate scintillation counter.
  • the compounds are dissolved to 10 mM in DMSO. Where needed, solutions are sonicated in a bath sonicator.
  • Table 4 provides the plC 50 values and % Remaining activity values at two concentrations (1 ⁇ and 0,1 ⁇ ) of the compounds according to the invention, obtained using the above mentioned kinase assay. - -
  • + indicates an IC50 > 1 ⁇
  • ++ indicates an IC50 of between 100 nM and 1 ⁇
  • +++ indicates an IC50 ⁇ 100nM

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés macrocycliques et des compositions contenant lesdits composés agissant en tant qu'inhibiteurs de la kinase, en particulier en tant qu'inhibiteurs de la kinase SIK, plus particulièrement SIK1, SIK2 et/ou SIK3, et/ou des mutants de ceux-ci, destinés au diagnostic, à la prévention et/ou au traitement des maladies associées à la kinase SIK. Par ailleurs, la présente invention concerne des procédés d'utilisation desdits composés, par exemple comme médicament ou agent diagnostique.
EP14719637.2A 2013-03-15 2014-03-14 Inhibiteurs macrocycliques de la kinase inductible par un sel Withdrawn EP2968326A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP14719637.2A EP2968326A1 (fr) 2013-03-15 2014-03-14 Inhibiteurs macrocycliques de la kinase inductible par un sel

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2013055389 2013-03-15
EP14719637.2A EP2968326A1 (fr) 2013-03-15 2014-03-14 Inhibiteurs macrocycliques de la kinase inductible par un sel
PCT/EP2014/055168 WO2014140313A1 (fr) 2013-03-15 2014-03-14 Inhibiteurs macrocycliques de la kinase inductible par un sel

Publications (1)

Publication Number Publication Date
EP2968326A1 true EP2968326A1 (fr) 2016-01-20

Family

ID=54842919

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14719637.2A Withdrawn EP2968326A1 (fr) 2013-03-15 2014-03-14 Inhibiteurs macrocycliques de la kinase inductible par un sel

Country Status (1)

Country Link
EP (1) EP2968326A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034007A2 (fr) * 2004-09-18 2006-03-30 Curagen Corporation Procedes permettant de traiter des troubles metaboliqes par la modulation de la serine/threonine kinase 2 inductible par des sels

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034007A2 (fr) * 2004-09-18 2006-03-30 Curagen Corporation Procedes permettant de traiter des troubles metaboliqes par la modulation de la serine/threonine kinase 2 inductible par des sels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014140313A1 *

Similar Documents

Publication Publication Date Title
AU2012314376B2 (en) Macrocyclic FLT3 kinase inhibitors
WO2014140313A1 (fr) Inhibiteurs macrocycliques de la kinase inductible par un sel
EP2970333B1 (fr) Inhibiteurs macrocycliques de la kinase lrrk2
JP6082397B2 (ja) マクロ環状ｌｒｒｋ２キナーゼ阻害剤
EP3194405B1 (fr) Inhibiteurs de la kinase lrrk2 macrocyclique
CA2906257A1 (fr) Inhibiteurs macrocycliques de la kinase rip2
EP3194407B1 (fr) Inhibiteurs de la kinase rip2 macrocyclique
WO2016146651A1 (fr) Inhibiteurs macrocycliques de récepteur kinase de type activine
EP2968326A1 (fr) Inhibiteurs macrocycliques de la kinase inductible par un sel
EP2760867B1 (fr) Inhibiteurs de kinase flt3 macrocycliques
HK1219481B (en) Macrocyclic lrrk2 kinase inhibitors
EP2968325A1 (fr) Inhibiteurs macrocycliques de la kinase rip2
NZ730758B2 (en) Macrocyclic rip2 kinase inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150929

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20171016

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180227